Perrigo Relies On New Products For Fiscal Second-Half Boost
By
Dan Schiff / Email the Author / “The Tan Sheet” Feb. 13, 2012, Vol. 20, No. 07
Sales & Earnings / Word Count: 729 / Article # 05120213009
Executive Summary
Planned launches of generic Claritin-D, Mucinex and Prevacid 24HR are expected to help Perrigo reach 12% to 14% consumer health care growth in fiscal 2012. Opportunities to gain from J&J and Novartis OTC recalls likely are minimal going forward, the private labeler says on its Q2 earnings call.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.